Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis

Figure 7

Tofacitinib inhibits the same IFN-γ- or IL-22-activated molecular pathways suppressed by SOCS1 or SOCS3. WB analysis was performed on protein lysates of HaCaT keratinocyte clones overexpressing SOCS1, SOCS2, or SOCS3, stimulated with IFN-γ (a) or IL-22 (b) or left untreated. Analysis was also performed on MOCK-transfected cells left untreated or treated with IFN-γ (a) or IL-22 (b), in the presence or absence of 5 μM tofacitinib. Both basal and phospho-STAT1, phospho-STAT3, and phospho-ERK1/2 were evaluated. Graphs show densitometric analysis of WB bands, and data are expressed means of densitometric units, calculated using two and four different keratinocyte clones for each transgene and mock clones to detect STATs and ERK1/2 proteins, respectively. , .

(a)

(b)

(c)